Small molecule

APIIC Releases Recommendations to Combat Rising U.S. Drug Shortages and Ensure Access to Life-Saving Medications

Retrieved on: 
Wednesday, January 24, 2024

“The collaboration necessary to develop a paper of this caliber is impressive,” said Tony Sardella, chair of the API Innovation Center.

Key Points: 
  • “The collaboration necessary to develop a paper of this caliber is impressive,” said Tony Sardella, chair of the API Innovation Center.
  • The APIIC report encourages pharmaceutical manufacturers and policy makers to address these vulnerabilities to national health security through the adoption of advanced biomanufacturing technologies and public incentive programs designed to reignite idle capacity at U.S. manufacturing facilities.
  • “For more than 200 years, U.S. Pharmacopeia has brought healthcare professionals, scientists, and regulators together to ensure quality and trust in our drugs,” said Dennis Hall, vice president, Advanced Manufacturing Technologies at U.S. Pharmacopeia (USP).
  • It follows developments and reports from the White House Office of Science and Technology , the National Economic Council (NEC) Director and the National Security Advisor (NSA), calling for a new approach aimed at guaranteeing Americans reliable access to essential medications.

Global Small Molecule Innovator CDMO Market Poised for Strong 6.5% CAGR Through 2031, Fueled by Rising Outsourcing Demand in Pharmaceutical Development - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 18, 2023

Increasing Demand for Outsourcing Services in Drug Development: Pharmaceutical companies are increasingly outsourcing complex and resource-intensive processes such as drug substance synthesis and drug product manufacturing to CDMOs.

Key Points: 
  • Increasing Demand for Outsourcing Services in Drug Development: Pharmaceutical companies are increasingly outsourcing complex and resource-intensive processes such as drug substance synthesis and drug product manufacturing to CDMOs.
  • Intellectual Property and Confidentiality Concerns: Intellectual property (IP) and confidentiality concerns pose a restraint on the Small Molecule Innovator CDMO market.
  • The Small Molecule Innovator CDMO market is segmented into product types, stage types, customer types, therapeutic areas, and regions.
  • Notable segments include:
    Product: Small Molecule API and Small Molecule Drug Product, with Small Molecule API exhibiting the highest CAGR during the forecast period.

Anima Biotech to Present at the 4th Annual RNA-Targeting Small Molecule Drugs hosted by CHI as part of the 18th Annual Drug Discovery Event

Retrieved on: 
Monday, April 10, 2023

BERNARDSVILLE, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Anima Biotech, the leader in the discovery of small molecule mRNA drugs and their mechanisms of action by phenotypic screening with AI driven MOA elucidation, today announced the company will give a presentation during the 18th Annual Drug Discovery Chemistry as part of the RNA-Targeting Small Molecule Drugs track of the Conference held from April 10th to April 13th, 2023 in San Diego, CA and virtually.

Key Points: 
  • BERNARDSVILLE, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Anima Biotech, the leader in the discovery of small molecule mRNA drugs and their mechanisms of action by phenotypic screening with AI driven MOA elucidation, today announced the company will give a presentation during the 18th Annual Drug Discovery Chemistry as part of the RNA-Targeting Small Molecule Drugs track of the Conference held from April 10th to April 13th, 2023 in San Diego, CA and virtually.
  • During the conference, Anima Biotech’s chief scientific officer and co-founder, Iris Alroy, Ph.D., will give a presentation titled, “Discovery of Small Molecule mRNA Modulators Using Phenotypic Screening with AI-Driven MoA Elucidation,” during the RNA Targeting Small Molecule Drugs track on Tuesday, April 11, 2023 from 8:10 – 8:40 a.m. PT.
  • The Drug Discovery Chemistry conference brings together experts from medicinal and biophysical chemistry in pharma, biotech and academia to discuss the exciting opportunities and advancements in drug discovery.
  • The RNA Targeting Small Molecule Drugs track highlights some of the innovative approaches and technologies being used to overcome obstacles faced in the field.

CAS Convenes Life Sciences Advisory Board to Reimagine the Future of Scientific Discovery

Retrieved on: 
Wednesday, April 5, 2023

CAS, a division of the American Chemical Society specializing in scientific information solutions, announced today its CAS Life Sciences Advisory Board.

Key Points: 
  • CAS, a division of the American Chemical Society specializing in scientific information solutions, announced today its CAS Life Sciences Advisory Board.
  • The board comprises a world-class panel of global thought leaders, directing the CAS scientific journey to align authoritative content with groundbreaking predictive technologies that span the spectrum of life sciences workflows.
  • CAS also continues to recruit additional members to ensure broad diversity and engagement.
  • “We are privileged to have this team of passionate global industry leaders partner with CAS to help drive new innovations in drug discovery,” said Manuel Guzman, President, CAS.

Xtalks Announces its Life Science Webinar Calendar for January 2023

Retrieved on: 
Wednesday, January 4, 2023

TORONTO, Jan. 4, 2023 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!

Key Points: 
  • See the Future Today
    Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.
  • Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.)
  • Xtalks helps Life Science professionals stay current with industry developments, trends and regulations.
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

Anima Biotech To Present And Participate In Panel Discussion At The 5th RNA Targeted Drug Discovery Summit

Retrieved on: 
Wednesday, December 14, 2022

During the conference, Anima Biotech’s chief business officer, Kevin Pong, Ph.D. will join the Biopharma & Investment Partnerships panel – Exploring the Future of RNA Investment & Collaborations Space for Small Molecules.

Key Points: 
  • During the conference, Anima Biotech’s chief business officer, Kevin Pong, Ph.D. will join the Biopharma & Investment Partnerships panel – Exploring the Future of RNA Investment & Collaborations Space for Small Molecules.
  • The panel takes place Wednesday, December 14, 2022 at 11:50 a.m.
  • Anima is advancing mRNA Lightning, a novel platform for the discovery of small molecule mRNA drugs and their mechanisms of action.
  • With our deep expertise in mRNA biology, we were able to advance them at unprecedented speed and success rate.

Philochem AG, Seibersdorf Labor GmbH and Isotopia announce supply, development, and manufacturing agreements

Retrieved on: 
Tuesday, December 13, 2022

OTELFINGEN, Switzerland, SEIBERSDORF, Austria and PETAH TIKVA, Israel, Dec. 13, 2022 /PRNewswire/ -- Philochem, Seibersdorf Laboratories and Isotopia Molecular Imaging have today announced that they have signed agreements that will help advance the next generation of Radiopharmaceutical Therapies for cancer treatment.

Key Points: 
  • Under these agreements, Isotopia will supply high quality 177 Lu-n.c.a to Seibersdorf Laboratories for the purpose of conducting development and manufacturing activities for Philochem's proprietary therapeutic candidate, OncoFAP-23.
  • Sammuele Cazzamalli, PhD, Head of Small Molecule Therapeutics at Philochem commented: " We are delighted to start working with Isotopia and Seibersdorf Laboratories on the manufacturing of our Targeted Radioligand Therapeutics.
  • The experienced Isotopia team, together with its nuclear pharmacy, cyclotron facility, 177Lu production site and sterile manufacturing plant, are a well-established platform for manufacturing and collaborations.
  • Isotopia creates collaborations between the scientific and medical community to further develop and experiment with new markers for imaging applications and molecular therapy.

Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Retrieved on: 
Monday, November 7, 2022

Incyte (Nasdaq:INCY) today announced that abstracts featuring data from its oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held November 8-12, 2022, in Boston and virtually.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that abstracts featuring data from its oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held November 8-12, 2022, in Boston and virtually.
  • We look forward to presenting data at the SITC Annual Meeting from our immuno-oncology pipeline, including our oral PD-L1 program, as we make progress toward our goal of identifying new solutions for patients with cancer who need additional options.
  • All accepted odd-numbered posters are available from 9:00 a.m. 9:00 p.m. EST on Thursday, November 10.
  • The virtual meeting platform will be available following the conclusion of the meeting for registered attendees until Monday, Jan. 9, 2023.

South Rampart Pharma Announces Presentation at Arrowhead's 16th Annual Pain Therapeutics Summit

Retrieved on: 
Friday, October 21, 2022

NEW ORLEANS, Oct. 21, 2022 /PRNewswire/ -- South Rampart Pharma ("South Rampart" or the "Company"), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that Hernan Bazan, MD, FACS, CEO and Co-Founder of South Rampart Pharma and the Endowed John Ochsner Professor of Cardiovascular Innovation at the Ochsner Clinic, will present at Arrowhead's 16th Annual Pain Therapeutics Summit.

Key Points: 
  • NEW ORLEANS, Oct. 21, 2022 /PRNewswire/ -- South Rampart Pharma ("South Rampart" or the "Company"), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that Hernan Bazan, MD, FACS, CEO and Co-Founder of South Rampart Pharma and the Endowed John Ochsner Professor of Cardiovascular Innovation at the Ochsner Clinic, will present at Arrowhead's 16th Annual Pain Therapeutics Summit.
  • Taking place in Washington, DC, on November 14-15, 2022, the Pain Therapeutics Summit is the US's premier conference covering pain research and emerging therapeutics.
  • South Rampart Pharma was recently issued a composition of matter US patent for its library of pain treatment candidates.
  • This enormous and urgent unmet medical need is the problem we've set out to solve at South Rampart Pharma.

ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022

SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced two upcoming poster presentations for CCX559, the Company’s investigational, highly potent, orally administered PD-L1 checkpoint inhibitor, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held November 8-12, 2022, in Boston, MA.

Key Points: 
  • Preclinical characterization has demonstrated that CCX559 blocks binding to PD-1 and CD80, and prevents PD-L1 inhibition of T cell activation.
  • CCX559, when orally administered in animal models, demonstrated anti-tumor efficacy, including the ability to induce complete responses.
  • The PD-L1/PD-1 interaction is one of the major immune checkpoints that limits the ability of effector T cells to destroy cancer cells.
  • ChemoCentryxis also developing CCX559, a highly potent orally administered small molecule PD-L1 checkpoint inhibitor, for the treatment of patients with solid tumors.